Home / Centerstage / 2014 / april / Week 3 /
Mylan Inc. raises its bid for Swedish drug maker Meda AB to $6.7 billion in an all-stock offer. The revised bid represents a 50% premium to Meda's share price when the initial offer was reported. If accepted, the deal would value Meda at approximately $6.7 billion, furthering Mylan's expansion in the pharmaceutical industry.
Friday, 25 April, 2014